Search
District Of Columbia Paid Clinical Trials
A listing of 851 clinical trials in District Of Columbia actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
697 - 708 of 851
District Of Columbia is currently home to 851 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes
Recruiting
The effects of consuming non-nutritive sweeteners (NNS) during pregnancy and lactation on infant obesity and cardiometabolic disease risk are not well understood. In this project, pregnant women who frequently consume NNS will be randomly assigned to an NNS-restriction intervention (NNS restriction during pregnancy and lactation or during lactation only) or a control group (no NNS restriction) to determine whether NNS consumption during pregnancy and/or lactation affects infant body composition,... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
12/11/2024
Locations: The George Washington University, Washington, District of Columbia
Conditions: Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy, Non-nutritive Sweeteners Consumption in Pregnancy And/or Lactation
Renal Retention in High Grade Upper Tract Urothelial Cancer
Recruiting
This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC), preferring to forego standard of care radical nephroureterectomy (RNU) surgery. Currently these patients would not be suitable candidates for neoadjuvant trials, as the patients intention is to forego surgery. The patients are also not candidates for metastatic trials, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Johns Hopkins University: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma Bladder
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Recruiting
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer.
This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/07/2024
Locations: MedStar Washington Hospital Center, Washington, D.C., District of Columbia
Conditions: Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Brain Oxygen Optimization in Severe TBI, Phase 3
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: MedStar Washington Hospital Center, Washington, DC, District of Columbia
Conditions: Brain Injuries, Traumatic
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population.
The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
ALL
Ages:
Between 5 years and 14 years
Trial Updated:
12/05/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Obesity, Childhood, Cancer, Survivorship
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies.
The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
Recruiting
Over 90% of children and adolescents diagnosed with acute lymphoblastic leukemia (ALL) will survive long term. Part of the successful treatment that patients receive is the delivery of chemotherapy directly into their spinal fluid via a spinal tap. This takes place approximately 20 times over the course of treatment. Most children and adolescents receive general anesthesia during this procedure to manage pain and anxiety. It is now understood that general anesthesia contributes to impairments in... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
12/03/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Acute Lymphoblastic Leukemia, Pediatric
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: a Pragmatic Trial
Recruiting
We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs.... Read More
Gender:
ALL
Ages:
Between 15 years and 21 years
Trial Updated:
12/03/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sexually Transmitted Diseases
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Recruiting
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Glioblastoma
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Cutaneous Melanoma, Stage II
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/24/2024
Locations: Children's National Research Institute - Children's National Hospital, Washington, District of Columbia
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Washington, District of Columbia
Conditions: Acute Respiratory Distress Syndrome, ARDS